Last reviewed 2026-05-25 · How we verify

Serotonin agonist - 13ug

University of Chicago · Phase 1 active Small molecule ✓ Verified May 2026 Quality 0/100

Serotonin agonist - 13ug is a Small molecule drug developed by University of Chicago. It is currently in Phase 1 development. Also known as: LSD.

A serotonin agonist, a small molecule with a dose of 13ug, was studied in a completed clinical trial at the University of Chicago. The trial, which was completed in 2024, investigated the mood effects of this serotonin agonist in healthy individuals.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Serotonin agonist - 13ug
Also known as	LSD
Sponsor	University of Chicago
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Mood Effects of Serotonin Agonists (PHASE1)
Mood Effects of Serotonin Agonists Extended (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Serotonin agonist - 13ug CI brief — competitive landscape report
Serotonin agonist - 13ug updates RSS · CI watch RSS
University of Chicago portfolio CI

Frequently asked questions about Serotonin agonist - 13ug

What is Serotonin agonist - 13ug?

Serotonin agonist - 13ug is a Small molecule drug developed by University of Chicago.

Who makes Serotonin agonist - 13ug?

Serotonin agonist - 13ug is developed by University of Chicago (see full University of Chicago pipeline at /company/university-of-chicago).

Is Serotonin agonist - 13ug also known as anything else?

Serotonin agonist - 13ug is also known as LSD.

What development phase is Serotonin agonist - 13ug in?

Serotonin agonist - 13ug is in Phase 1.

Manufacturer: University of Chicago — full pipeline
Also known as: LSD

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing